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Abstract: Otomycosis is a fungal infection of the external ear; middle ear and open mastoid cavity.
Meyer first described the fungal infection of the external ear canal in 1884. External ear canal has 
an ideal warm humid environment for the proliferation of fungus.
life threatening, it can presents a challenging and frus
due to long term treatment and high rate of recurrence.
immunocompromised patients as compared to immunocompetent persons. Recurrence rate is high 
in immunocompromised patients and they need longer duration treatment and complications are 
more frequent in immunocompromised patients. 
In  the  recent  years;  opportunistic  fungal  infections  are  gaining  greater  importance  in  human 
medicine  as  a  result  of  possibly  huge  number  o
immunocompromised  patients,  it is  important  that the treatment  of  otomycosis be  vigorous,  to 
minimize  complications  such  as  hearing  loss,  tympanic  membrane  perforations  and  invasive 
temporal bone infection.
5 Fungal culture
Hematological investigations play a very important role in confirming the diagnosis and immunity 
status of the patients. In diabetic patients with otomycosis, along with antifungal therapy, blood 
sugar levels should be controlled with medical therapy to prevent complications.
Introduction: Otomycosis or fungal otitis externa
typically  been  described  as  fungal  infection  of  the 
external auditory canal with infrequent complications 
involving  the  middle  ear.
3  Fungi  causes  10%  of  all 
cases of otitis externa.
6 In the recent years there has 
been an increase in the incidence as a result of possibly 
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Otomycosis is a fungal infection of the external ear; middle ear and open mastoid cavity.
Meyer first described the fungal infection of the external ear canal in 1884. External ear canal has 
an ideal warm humid environment for the proliferation of fungus.
2 Although this disease is rarely 
life threatening, it can presents a challenging and frustrating situation for the otologist and patients 
due to long term treatment and high rate of recurrence.
3 Otomycosis is seen more frequently in 
immunocompromised patients as compared to immunocompetent persons. Recurrence rate is high 
patients and they need longer duration treatment and complications are 
more frequent in immunocompromised patients. 
In  the  recent  years;  opportunistic  fungal  infections  are  gaining  greater  importance  in  human 
medicine  as  a  result  of  possibly  huge  number  of  immunocompromised  patients.
immunocompromised  patients,  it is  important  that the treatment  of  otomycosis be  vigorous,  to 
minimize  complications  such  as  hearing  loss,  tympanic  membrane  perforations  and  invasive 
Fungal cultures are essential to confirm the diagnosis.
Hematological investigations play a very important role in confirming the diagnosis and immunity 
status of the patients. In diabetic patients with otomycosis, along with antifungal therapy, blood 
d be controlled with medical therapy to prevent complications.
Otomycosis or fungal otitis externa has 
typically  been  described  as  fungal  infection  of  the 
external auditory canal with infrequent complications 
Fungi  causes  10%  of  all 
In the recent years there has 
result of possibly 
huge number of immunocompromised patients. In the 
past, there were controversies regarding the prevalence 
and even existence of otomycosis. It is now considered 
to  be  a  definitive  clinical  entity  and  a  continuing 
problem.
1  Although  there  has  been  controversy  with 
respect  to  whether  the  fungi  are  the  true  infective 
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Otomycosis is a fungal infection of the external ear; middle ear and open mastoid cavity.
1
Meyer first described the fungal infection of the external ear canal in 1884. External ear canal has 
Although this disease is rarely 
trating situation for the otologist and patients 
Otomycosis is seen more frequently in 
immunocompromised patients as compared to immunocompetent persons. Recurrence rate is high 
patients and they need longer duration treatment and complications are 
In  the  recent  years;  opportunistic  fungal  infections  are  gaining  greater  importance  in  human 
f  immunocompromised  patients.
4  In 
immunocompromised  patients,  it is  important  that the treatment  of  otomycosis be  vigorous,  to 
minimize  complications  such  as  hearing  loss,  tympanic  membrane  perforations  and  invasive 
s are essential to confirm the diagnosis.
Hematological investigations play a very important role in confirming the diagnosis and immunity 
status of the patients. In diabetic patients with otomycosis, along with antifungal therapy, blood 
d be controlled with medical therapy to prevent complications.
huge number of immunocompromised patients. In the 
past, there were controversies regarding the prevalence 
and even existence of otomycosis. It is now considered 
to  be  a  definitive  clinical  entity  and  a  continuing 
e  has  been  controversy  with 
respect  to  whether  the  fungi  are  the  true  infective Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
agents  versus  mere  colonization  of  the  species  as  a 
result of compromised local host immunity secondary 
to  bacterial  infection,  most  clinical  and  laboratory 
evidence shows that otomycosis as a true pathological 
entity.
3
General cellular immunity is reduced in situations 
such as diabetes, steroid administration, HIV infection, 
chemothraphy  and  malignancy  (especially  those 
involving  cells  of  immune  system).This  makes  an 
immunocompromised  host  susceptible  to  fungal 
infections.  Normal  bacterial  flora  is  one  of  the  host 
defense  mechanism  against  fungal  infections  .This 
mechanism  is  altered  in  patient  patients  using 
antibiotics ear drops and cause otomycosis.
2
Otomycosis  is  sporadic  and  caused  by  a  wide 
variety of fungi, most of which are saprobe occurring 
in  diverse type  of  environmental  material.
4  It  affects 
10%  of  the  population  in  their  life  time.
6  Fungi  are 
abundant in soil or sand which contains decomposing 
vegetable matter. This is desiccated rapidly in tropical 
sun and blown in wind as small dust particles. The air 
borne fungal spores are carried by water vapors, a fact 
which correlates the higher rates of infection, monsoon 
when  relative  humidity  rises  to  80%.
7  Many  studies 
have shown that the incidence was more common in 
third decade of life. Higher incidence in young adults 
may be attributed to the fact that these people are more 
exposed to the mycelia, whereas extreme age groups 
are not exposed to the pathogens.
3,8,9,10
Common symptoms of otomycosis are itching, ear 
pain,  ear  discharge,  blocking  decreased  hearing  and 
tinnitus.
3,8,10  The  correct  diagnosis  of  otomycosis 
requires a high index of suspicion, given that the most 
common  presenting  symptoms,  otalgia  and  otorrhea, 
are nonspecific.
5
A few conditions may predispose an individual for 
otomycosis (table 1).
3,11 An immunocompromised host 
is  more susceptible to  otomycosis.  Patients  suffering 
from  diabetes,  lymphoma,  transplantation  patients, 
patient  receiving  chemotherapy  or  radiation  therapy 
and  AIDS  patients,  are  also  at  increased  risk  for 
potential complications from otomycosis
9.
Table 1: Showing predisposing factors for otomycosis
1 Trauma
2 Relative high percentage humidity in external ear canal
3 Epithelial debris in various stages of chemical 
breakdown
4 High temperature which closely approximate body 
temperature
5 General diseases such as diabetes mellitus
6 Immunocompromised hosts
7 Increased use of topical antibiotic/steroid preparations
Ear  cleaning  habits  may  also  contribute  to 
pathogenesis. Traumatized external ear canal skin can 
present  a  favorable  condition  for  fungal 
growth.
11Clinical  studies  have  shown  that  otological
procedures,  particularly  those  that  result  in  mastoid 
cavity, as a potential risk factor for otomycosis.
3 The 
factors that predisposes to otomycosis in the previously 
operated ears are;
1. Recurrent  drainage,  antibiotic/antifungal 
applications  – this  may  alter  the  local 
environment of the external ear canal and allow 
super infection by nasocomial fungi.
2. Alteration in  the  anatomy by canal  wall  down 
procedures  may  also  produce  changes  in  the 
cerumen  production  or  relative  humidity  that 
favor fungal growth.
3
Among  the  fungi,  the  species  of  Aspergillus  are 
considered  the  predominant  organisms  implicated  in 
the etiology of otomycosis in tropical countries.
4 Many 
studies  have shown  that  Aspergillus  species was the 
commonly  isolated  fungus  and  Candida  was  next 
commonly  isolated  fungi,  in  immunocompetent 
hosts.
8,9,10,11 Studies  by  Kishore  et  al
12 and 
Viswanatha
13 have  shown  that  Candida  species  was 
mainly  responsible  for  otomycosis  in 
immunocompromised  hosts.  Infection  with  Candida 
can be more difficult to detect clinically because of its 
lack of characteristic appearance like Aspergillus and 
can  present  as  otorrhea  not  responding  to  aural 
antimicrobials.  Otomycosis  attributed  to  Candida  is 
often identified by cultural data.
3
Pseudallescheria  boydii  is  a  saprophytic  fungus 
capable  of  causing  invasive  fungal  infections  in 
humans,  especially  in  immunocompetent  hosts.  This 
fungus is morphologically similar to Aspergillus but is 
resistant  to  conventional  systemic  antifungal  therapy 
with amphotericin B.
14
Many  studies  have  shown  that  otomycosis  is 
predominantly unilateral disease in immunocompetent 
hosts.
8,11,15 In  a  recent  study  by  Viswanatha  et  al
13
bilateral  involvement  was  seen  more  in 
immunocompromised group than in immunocompetent 
group.
Fungal  cultures  are  essential  to confirm  the 
diagnosis.  Hematological  investigations  play  a  very 
important  role  in  confirming  the  diagnosis  and 
immunity  status  of  the  patients.  In  diabetic  patients 
with  otomycosis,  blood  sugar  levels  should  be 
controlled  with  medical  therapy  to  prevent 
complications  due  to  otomycosis.  All  the  relevant 
hematological  investigations  should  be  done  in 
immunocompromised patients.
Complications  of  otomycosis  includes  tympanic 
membrane  perforation,  hearing  loss  and  invasive 
temporal  bone  infection  (table  2).
5,16 Tympanic Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
membrane perforation can occur as a complication of 
otomycosis  that  starts  in  an  ear  with  an  intact  ear 
drum.
5 In  a  clinical  study  by  Ram  Kumar,
16 the 
incidence  of  tympanic  membrane  perforation  in 
otomycosis was found to be 11% and perforation was 
more  common  with  otomycosis  caused  by  Candida 
albicans. Tympanic membrane perforation is seen more 
commonly  in  immunocompromised  patients  than  in 
immunocompetent patients.
13 This may be due to the 
fact  that  majority  of  the  cases  of  otomycosis  in 
immunocompromised patients are caused by Candida 
albicans.
13
Table 2: Showing complications of otomycosis
1 Tympanic membrane perforation 
2 Hearing loss 
3 Invasive temporal bone infection
4 Fungal otomastoiditis
5 Meningoencephalitis
Most of the perforations were behind the handle of 
the  malleus. The mechanism of perforation has been 
attributed  to  mycotic  thrombosis  of  the  tympanic 
membrane blood vessels resulting in avascular necrosis 
of  tympanic  membrane.
5,17 There  may  not  be  any 
clinical  features  predictive  of  tympanic  membrane 
perforation. Tympanic membrane involvement is likely 
a consequence of fungal inoculation in the most medial 
aspect of the external canal or direct extension of the 
disease from adjacent skin.
3
In  immunocompromised  patients  malignant  otitis 
externa  can,  rarely,  present  as  an  aggressive 
angioinvasive fungal infection of the temporal bone.
2
Invasive  Aspergillus  otomastoiditis  resulting  from  a 
tympanogenic source is a rare entity but is being found 
with  increased  frequency  in  immunocompromised 
hosts.  Invasive  Aspergillosis  is  most  commonly 
observed  in  patients  with  lymphoproliferative 
disorders,  but  it  may  occur  in  variety  of  diseases 
characterized  by  defective  humoral  or  cell-mediated 
immunity.
18 Aspergillus and Mucor, have a propensity 
to  invade  arterial  walls  in  immunocompromised 
patients,  especially  uncontrolled  diabetes  mellitus, 
leading to thrombosis and tissue infarction.
19
Strauss and Fine
20 reported two cases of Aspergillus 
otomastoiditis  caused  by  Aspergillus  fumigatus  in 
AIDS  patients.  Haruna  et  al
19 reported  a  case  of 
invasive  fungal  temporal  bone  infection  caused  by 
Mucor,  leading  to  meningoencephalitis  in  an 
immunocompromised  patient.  Nicolas  et  al
14 have 
reported  a  case  of  invasive  Pseudallescheria  boydii 
fungal infection of the temporal bone in a patent with 
AIDS.
Treatment  of  otomycosis  includes  microscopic 
suction  clearance  of  fungal  mass,  discontinuation  of 
topical  antibiotics  and  treatment  with  antifungal  ear 
drops for three weeks. Ear should be kept dry for three 
weeks.  Small  perforations  heal  spontaneously  and 
larger perforation requires myringoplasty.
13
Bassouni  et  al
21 studied  the  effects  of  antifungal 
agents and found that clotrimazole ear drops was more 
effective  antifungal  agent  in  the  treatment  of 
otomycosis. According to Stern et al
22 and Jackman et 
al,
23 clotrimazole  ear  drops  is  the  most  effective 
antifungal  agent.  In  another  study  fluconozole  ear 
drops  was  found  to  be  more  effective  in  treating 
otomycosis.
24 Clotrimazole and fluconozole ear drops 
should be used for 3-4 weeks.
Oral  and  intravenous  preparations  of  antifungal 
agents  are  available  for  severe  infections  in 
immunocompromised  patients.
2  Oral  antifungal  are 
unlikely to succeed in the absence of adequate local 
care.
3 These antifungal agents should be given for 3-4 
weeks depending on the patient’s condition.
Fungal  infections  of  the  mastoid  cavity  of  the 
immunocompromised  patients  who  have  undergone 
canal  wall  down  mastoidectomy  are  seen  quite 
frequently and they require prolonged treatment with 
antifungal  ear  drops  and  oral  antifungal  drugs.  The 
recommended  treatment  for  patients  suffering  from 
fungal  otomastoiditis  includes  surgical  debridement 
and systemic antifungal therapy with amphotericin B 
being the gold standard.
14 Antifungal agents should be 
given  for  3-4  weeks  depending  on  the  patient’s 
condition.
Conclusion: Diagnosis  and  management  of 
otomycosis  in  can  be  really  challenging  in 
immunocompromised  patients.  Recurrences  are 
common  in  immunocompromised  patients  than  in 
immunocompetent  patients.  Eradication  the  disease 
may be difficult in immunocompromised patients, who 
have  undergone  canal  wall  down  mastoidectomy.  In 
these patient prolonged antifungal therapy is required.
Otologist  should  remain  alert  for  otomycosis  and 
should consider obtaining hematological investigations 
and fungal cultures when this disease is suspected in 
immunocompromised host.
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